Dexpak Taperpak and Alcohol/Food Interactions
There are 2 alcohol/food/lifestyle interactions with Dexpak Taperpak (dexamethasone).
Dexamethasone High Blood Pressure (Hypertension)
Moderate Potential Hazard, Moderate plausibility
corticosteroids - fluid retention
Corticosteroids may cause hypernatremia, hypokalemia, fluid retention, and elevation in blood pressure. Large doses of any corticosteroid can demonstrate these effects, particularly if given for longer periods. Therapy with corticosteroids should be administered cautiously in patients with preexisting fluid retention, hypertension, congestive heart failure, and/or renal dysfunction. Dietary sodium restriction and potassium supplementation may be advisable.
References
- (2001) "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc
- (2001) "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn
- (2001) "Product Information. Decadron (dexamethasone)." Merck & Co., Inc
- (2001) "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc
- (2001) "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn
- (2001) "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb
- (2001) "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc
- (2001) "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb
- (2001) "Product Information. Celestone (betamethasone)." Schering Corporation
- (2021) "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc., SUPPL-5
- (2023) "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US)
Dexamethasone High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)
Moderate Potential Hazard, Moderate plausibility
corticosteroids - hyperlipidemia
Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods. Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.
References
- Seale JP, Compton MR (1986) "Side-effects of corticosteroid agents." Med J Aust, 144, p. 139-42
- (2001) "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc
- (2001) "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn
- (2001) "Product Information. Decadron (dexamethasone)." Merck & Co., Inc
- (2001) "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc
- (2001) "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn
- (2001) "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb
- (2001) "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc
- (2001) "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb
- (2001) "Product Information. Celestone (betamethasone)." Schering Corporation
Dexpak Taperpak drug interactions
There are 777 drug interactions with Dexpak Taperpak (dexamethasone).
Dexpak Taperpak disease interactions
There are 23 disease interactions with Dexpak Taperpak (dexamethasone) which include:
- infections
- prematurity
- (+) tuberculin test
- cirrhosis
- depression/psychoses
- diabetes
- electrolyte imbalance
- fluid retention
- GI perforation
- hyperadrenocorticalism
- hyperlipidemia
- hypothyroidism
- liver disease
- MI
- myasthenia gravis
- myopathy
- ocular herpes simplex
- ocular toxicities
- osteoporosis
- PUD
- scleroderma
- strongyloidiasis
- thromboembolism
Report options
More about Dexpak Taperpak (dexamethasone)
- Dexpak Taperpak consumer information
- Check interactions
- Compare alternatives
- Reviews (2)
- Latest FDA alerts (9)
- Side effects
- Dosage information
- During pregnancy
- Drug class: glucocorticoids
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
